URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Arsani William Biography and Net Worth

Director of Design Therapeutics

Arsani William, M.D. has served as a member of our board of directors since January 2021. Dr. William has served as Managing Partner and Chief Investment Officer of Logos Capital since its founding in 2019. Prior to founding Logos, Dr. Williams served as an investment professional at Farallon Capital Management. Dr. Williams holds an M.D. from Harvard Medical School where he was a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University.

How do I contact Arsani William?: The corporate mailing address for Dr. William and other Design Therapeutics executives is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. Design Therapeutics can also be reached via phone at 858-293-4900 and via email at [email protected]. Learn More on Arsani William's contact information.
Has Arsani William been buying or selling shares of Design Therapeutics?: Arsani William has not been actively trading shares of Design Therapeutics within the last three months. Most recently, Arsani William sold 814,874 shares of the business's stock in a transaction on Friday, August 9th. The shares were sold at an average price of $4.25, for a transaction totalling $3,463,214.50. Learn More on Arsani William's trading history.
Are insiders buying or selling shares of Design Therapeutics?: In the last year, Design Therapeutics insiders bought shares 2 times. They purchased a total of 26,965 shares worth more than $99,750.38. In the last year, insiders at the sold shares 2 times. They sold a total of 818,680 shares worth more than $3,487,078.12. The most recent insider tranaction occured on December, 18th when Director Deepa Prasad sold 3,806 shares worth more than $23,863.62. Insiders at Design Therapeutics own 31.2% of the company. Learn More about insider trades at Design Therapeutics.
Information on this page was last updated on 12/18/2024.

Arsani William Insider Trading History at Design Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/9/2024	Sell	814,874	$4.25	$3,463,214.50
3/21/2022	Buy	25,000	$18.99	$474,750.00
8/31/2021	Buy	40,000	$15.45	$618,000.00

Arsani William Buying and Selling Activity at Design Therapeutics

Design Therapeutics Company Overview

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Today's Range

Now: $6.25

$5.86

$6.38

50 Day Range

MA: $5.90

$5.15

$7.50

2 Week Range

Now: $6.25

$2.24

$7.77

Volume

578,167 shs

Average Volume

236,970 shs

Market Capitalization

$353.88 million

P/E Ratio

N/A

Dividend Yield